A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), In Patients with Her2-Positive Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR” Study

Grant

Date/time Interval

  • January 4, 2019 - January 3, 2024
  • Total Award Amount

  • 140100.00
  • Direct Costs

  • 107770.00
  • Sponsor Award Id

  • Contributor

  • Rocque M.D., Gabrielle   Investigator  
  • Stringer-Reasor M.D., Erica   Investigator